{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:12:29Z","timestamp":1767924749273,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A bioanalytical method was developed and validated for determining lurasidone (LUR) in rat plasma. The analyte and internal standard were extracted from rat plasma using a liquid\u2013liquid extraction method. The mobile phase consisted of methanol, acetonitrile and water, with an ion pairing agent, 0.1% heptafluorobutyric acid, added to minimise the matrix effect. The detection was achieved using a tandem mass spectrometer (API 2000) in positive ion multiple reaction monitoring mode. All parameters were validated, including selectivity, specificity, carry\u2010over effect, linearity, precision, accuracy, matrix effect, sensitivity and stability. The linearity range was from 5.0 to 1200.0\u00a0ng\/mL with a correlation coefficient of &gt;0.99. The accuracy ranged from 100.00% to 110.22% across the quality control range. The mean absolute recovery from matrix samples for LUR and the internal standard was found to be 68.46% and 67.25%, respectively, and the relative recovery was found to be 73.89% and 77.44%, respectively. This method can determine LUR concentrations in rat plasma samples up to 12\u2009h after oral administration, aiding in LUR pharmacokinetic (PK) investigations in rats. The method's reproducibility on a conventional LC\u2013MS\/MS system and a shorter run time of 3.0\u00a0min make it an appealing bioanalytical method for quantifying LUR in PK studies.<\/jats:p>","DOI":"10.1002\/bmc.5764","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T05:50:05Z","timestamp":1699422605000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bioanalytical liquid chromatography\u2013tandem mass spectrometry method development and validation for quantification of lurasidone in rat plasma using ion pairing agent"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-7663","authenticated-orcid":false,"given":"Madhura","family":"Rajadhyaksha","sequence":"first","affiliation":[{"name":"SPPSPTM, SVKM's Narsee Monjee Institute of Management Studies  Mumbai India"},{"name":"Sitec Labs Ltd.  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Londhe","sequence":"additional","affiliation":[{"name":"SPPSPTM, SVKM's Narsee Monjee Institute of Management Studies  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.12991\/mpj.2017.32"},{"key":"e_1_2_9_3_1","unstructured":"CDER FDA. (2018).Bioanalytical method validation guidance for industry bioanalytical method validation guidance for industry."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10337-012-2294-5"},{"key":"e_1_2_9_5_1","unstructured":"ICH. (2022).Guideline bioanalytical method validation and study sample analysis M10."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3651"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1625"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800871-3.00007-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.11.024"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1698"},{"key":"e_1_2_9_12_1","unstructured":"RivaMA.An Update of the Preclinical Profile of Lurasidone.;2015 E\u2010bPC 67\u201372."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.626897"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.12.036"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:21:05Z","timestamp":1760055665000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/bmc.5764"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5764","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"2023-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5764"}}